In the ®rst trimester of pregnancy the biochemical markers free b-hCG and pregnancy associated plasma protein-A (PAPP-A) are used for the prenatal screening of trisomy 21, either alone or in combination with nuchal translucency (NT) thickness. In this study, I have analysed the distribution of these
First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free β-hCG and PAPP-A
✍ Scribed by Kevin Spencer; Kypros H. Nicolaides
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 45 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0197-3851
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
In a study of 50 cases of trisomy 18 compared with 947 controls we have found the median multiple of the median (MoM) of maternal serum free human chorionic gonadotrophin to be significantly decreased (0.281 MoM) in samples collected between the 10th and 14th week of gestation. Similarly, maternal s
In 42 cases of trisomy 13 at 10±14 weeks of gestation, compared with 947 controls, the median multiple of the median (MoM) of maternal serum free b-human chorionic gonadotrophin (b-hCG) and pregnancy associated plasma protein A (PAPP-A) was signi®cantly decreased (0.506 MoM and 0.248 MoM respectivel
In a study of 2923 normal pregnancies and 203 pregnancies affected by trisomy 21 we have shown a signi®cant difference in the median MoM of the markers: fetal nuchal translucency, maternal serum free b-hCG and PAPP-A in the presence of a female fetus compared with a male fetus. For maternal serum fr
The purpose of this case-control study was to examine the association of first-trimester concentrations of free beta-human chorionic gonadotropin (free beta-hCG) and pregnancy-associated plasma protein A (PAPP-A) in maternal serum with subsequent preterm delivery or small-for-gestational age (SGA) f